Acurx Shares Owned by Insiders

ACXP
 Stock
  

USD 3.45  0.15  4.55%   

Acurx Pharmaceuticals LLC fundamentals help investors to digest information that contributes to Acurx Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Acurx Stock. The fundamental analysis module provides a way to measure Acurx Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Acurx Pharmaceuticals stock.
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.
  

Acurx Shares Owned by Insiders Analysis

Acurx Pharmaceuticals' Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
Insiders Shares 
 = 
Executives Shares 
Employees 
More About Shares Owned by Insiders | All Equity Analysis

Current Acurx Pharmaceuticals Shares Owned by Insiders

    
  21.18 %  
Most of Acurx Pharmaceuticals' fundamental indicators, such as Shares Owned by Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Acurx Pharmaceuticals LLC is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
Compare to competition

Based on the latest financial disclosure, 21.18% of Acurx Pharmaceuticals LLC are shares owned by insiders. This is 39.53% higher than that of the Healthcare sector and 49.37% higher than that of the Biotechnology industry. The shares owned by insiders for all United States stocks is 109.91% lower than that of the firm.

Acurx Shares Owned by Insiders Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Acurx Pharmaceuticals' direct or indirect competition against its Shares Owned by Insiders to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Acurx Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Acurx Pharmaceuticals by comparing valuation metrics of similar companies.
Acurx Pharmaceuticals is currently under evaluation in shares owned by insiders category among related companies.

Acurx Fundamentals

About Acurx Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Acurx Pharmaceuticals LLC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Acurx Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Acurx Pharmaceuticals LLC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is based in Staten Island, New York. Acurx Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 3 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Acurx Pharmaceuticals without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Portfolio Suggestion Now

   

Portfolio Suggestion

Get suggestions outside of your existing asset allocation including your own model portfolios
All  Next Launch Module

Pair Trading with Acurx Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Acurx Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Acurx Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving together with Acurx Pharmaceuticals

+0.8APGNApexigen Symbol ChangePairCorr
The ability to find closely correlated positions to Acurx Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Acurx Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Acurx Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Acurx Pharmaceuticals LLC to buy it.
The correlation of Acurx Pharmaceuticals is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Acurx Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Acurx Pharmaceuticals LLC moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Acurx Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Please continue to Acurx Pharmaceuticals Piotroski F Score and Acurx Pharmaceuticals Altman Z Score analysis. You can also try Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.

Complementary Tools for analysis

When running Acurx Pharmaceuticals LLC price analysis, check to measure Acurx Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acurx Pharmaceuticals is operating at the current time. Most of Acurx Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Acurx Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Acurx Pharmaceuticals' price. Additionally, you may evaluate how the addition of Acurx Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Go
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Go
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Go
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Go
Fundamental Analysis
View fundamental data based on most recent published financial statements
Go
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Go
Is Acurx Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Acurx Pharmaceuticals. If investors know Acurx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Acurx Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
40 M
Return On Assets
(0.55) 
Return On Equity
(0.95) 
The market value of Acurx Pharmaceuticals LLC is measured differently than its book value, which is the value of Acurx that is recorded on the company's balance sheet. Investors also form their own opinion of Acurx Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Acurx Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Acurx Pharmaceuticals' market value can be influenced by many factors that don't directly affect Acurx Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Acurx Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Acurx Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Acurx Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.